Frances Walocko, MD, MEng
Mohs Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Mohs Micrographic Surgery and Reconstruction
- Dermatologic Surgery
- Laser- and Light-Based Dermatology
Request an Appointment
About Me
- Assistant Attending Dermatologist
I am a dermatologic surgeon specializing in Mohs micrographic surgery for the treatment of skin cancers, such as basal cell carcinoma, squamous cell carcinoma, and melanoma. Additionally, I have experience in treating rare skin tumors, including:
- Dermatofibrosarcoma protuberans
- Sebaceous carcinoma
- Microcystic adnexal carcinoma
I also have extensive training in cosmetic dermatology, with a special focus on non-surgical approaches to scar management. These treatment strategies include laser and light devices, as well as topical therapies (medications applied to the skin).
I see patients at Memorial Sloan Kettering Skin Cancer Center Hauppauge.
Read more
I believe that high-quality skin cancer care is comprehensive (care for the whole patient and all their needs) and includes both non-surgical and surgical options. I am a strong patient advocate and am attentive to personal preferences on treatment and quality of life. I work closely with doctors in other specialties, like medical oncology, to develop treatment plans that meet each patient’s goals.
Skin cancer is common on delicate areas of the body, such as the cheeks or nose. Mohs micrographic surgery is a tissue-sparing procedure used to remove skin cancer in sensitive areas where it’s important to preserve as much skin as possible, like the face. This highly-precise surgery allows us to take out the skin cancer while removing the least amount of healthy skin. My goal is to not only to help patients feel as comfortable as possible during skin cancer removal, but to also ensure that they are confident in and happy with the cosmetic results of skin cancer removal.
Outside of the clinic, I enjoy spending time with my husband, baby boy, and dog. We love taking family walks outside and exploring the various beaches on Long Island (with lots of sunscreen)!
A Mohs surgeon is a doctor with special training in treating skin cancer with Mohs surgery. This surgery removes cancer while keeping healthy tissue safe.
My Specialties
- Mohs Micrographic Surgery and Reconstruction
- Dermatologic Surgery
- Laser- and Light-Based Dermatology
- Cosmetic Dermatology
- Cutaneous Oncology
- Scar Treatment
Education
- MD, University of Michigan
- MEng, University of Michigan
Residencies
- Dermatology, University of Texas Southwestern Medical Center
Fellowships
- Mohs Micrographic Surgery & Dermatologic Oncology, Northwestern University
Board Certifications
- Dermatology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Walocko sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Walocko F, Christensen RE, Worley B, Alam M. Cutaneous Mesenchymal Sarcomas. Dermatol Clin. 2023 Jan;41(1):133-140. doi: 10.1016/j.det.2022.07.011. Epub 2022 Oct 28. PMID: 36410974.
Walocko FM, Carr C, Srivastava D, Nijhawan RI. Margin Size for Unique Skin Tumors Treated With Mohs Micrographic Surgery: A Survey of Practice Patterns. Cutis. 2022 Sep;110(3):E21-E24. doi: 10.12788/cutis.0633. PMID: 36446119.
Walocko F, Chelliah P, Kolitz E, Awerman J, Nijhawan RI, Srivastava D. Basal cell carcinoma histopathologic upgrading and Mohs micrographic surgery: a single institution, retrospective review. Arch Dermatol Res. 2022 Sep;314(7):705-707. doi: 10.1007/s00403-021-02212-3. Epub 2021 Mar 8. PMID: 33683445.
Read more
Walocko FM, Ly BC, White MS, Chen SC, Yeung H. Health-related quality of life measures and immune checkpoint inhibitors: A systematic review. J Am Acad Dermatol. 2020 Apr;82(4):1004-1006. doi: 10.1016/j.jaad.2019.10.042. Epub 2019 Nov 1. PMID: 31678470; PMCID: PMC7078062.
Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Metastatic Merkel cell carcinoma response to nivolumab. J Immunother Cancer. 2016 Nov 15;4:79. doi: 10.1186/s40425-016-0186-1. Erratum in: J Immunother Cancer. 2017 Mar 6;5:27. PMID: 27879975; PMCID: PMC5109712.
Visit PubMed for a full listing of Dr. Walocko’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Frances Walocko discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].